Drug Trial Radar · NCT01380938
Different Ribavirin Dosages and Different Duration of Treatment in Combination With PegInterferon in Patients With Genotype 2 and 3 (WRITE)
Last checked: Nov 20, 2026Latest source record: Mar 24, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,150
Actual
Start
Dec 1, 2018
Primary completion
Nov 30, 2019
Study completion Nov 30, 2019
Sponsor
- Lead sponsor
- Casa Sollievo della Sofferenza IRCCSAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Casa di Cura Mater Dei; IRCCS L. Spallanzani; Ospedale Francesco Ferrari; Azienda Ospedaliero Universitaria di Sassari; Fondazione IRCCS Policlinico San Matteo di Pavia; S. Anna Hospital; Azienda Ospedaliero-Universitaria, Catania; Ospedale di Venosa; Ospedale Monsignor R. Dimiccoli, Barletta; IRCCS De Bellis, Castellana; USL Napoli 1; Ospedale San Giuseppe Moscati, Avellino; Cardarelli Hospital; Ospedale Civile Vittorio Emanuele II, Bisceglie; Azienda Ospedaliero-Universitaria Careggi; Azienda Ospedaliera V. Cervello; Ospedale Civile Spirito Santo; Ospedale di Canosa di Puglia; University of Palermo; San Camillo Hospital, Rome; Campus Bio-Medico University; Ospedale Sandro Pertini, Roma; Ospedali Riuniti di Foggia; Ospedale SS. Annunziata, Taranto; Ospedale di Mottola; Ospedale Santa Caterina Novella, Galatina; University of Florence; Valduce Hospital; University of Bari; Azienda Ospedaliera, Siracusa; Azienda Ospedaliera, Lucca
- First posted
- Jun 27, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
WRITE study aim at identifying the effectiveness of an innovative individualized schedule of treatment as compared to standard regimen in patients with chronic HCV genotype 2 and 3.
Conditions
- Chronic Hepatitis
Interventions
Peginterferon alpha-2a + RibavirinDrug
Administration of ribavirin at a dosage of 1000 or 1200 mg per day based on body weight \< or \> 75 kg for 24 weeks (Arm A). Treatment duration of 48 weeks with standard fixed dose of ribavirin (800 mg/day) (Arm B). These schedules will be compared with diagram of standard therapy with 800 mg daily of ribavirin for 24 weeks (Arm C)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Sustained virological Response (SVR)Time frame: 6 months after the end of treatment
Locations
35 sites in 1 country. Site status is shown where the registry gives one.
Infectious Diseases Unit
Avellino, Italy
Clinical Medicine Unit "Mater Dei"
Bari, Italy
Università di Bari
Bari, Italy
Medicine Unit
Barletta, Italy
Infectious Diseases Unit "V. Emanuele"
Bisceglie, Italy
Medicine Unit
Canosa di Puglia, Italy
Hepatology Unit
Casarano, Italy
IRCCS "De Bellis"
Castellana Grotte, Italy
Hepatology Unit
Catania, Italy
Infectious Diseases Unit
Catania, Italy
Gastroenterology Unit
Como, Italy
Gastroenterology Unit Arcispedale "S. Anna"
Ferrara, Italy
Gastroenterology Unit
Florence, Italy
Internal Medicine University of Firenze
Florence, Italy
Gastroenterology Unit
Foggia, Italy
Infectious Diseases
Foggia, Italy
Gastroenterology Unit
Galatina, Italy
Infectious Diseases
Lucca, Italy
Gastroenterology Unit
Mottola, Italy
Gastroenterology Unit "Cardarelli"
Naples, Italy
USL Napoli 1
Naples, Italy
Hospital "V. Cervello"
Palermo, Italy
Medical Clinic University of Palermo
Palermo, Italy
Infectious Diseases Unit IRCCS "San Matteo"
Pavia, Italy
Campus Biomedico University
Roma, Italy
Hepatology Unit "S. Pertini"
Roma, Italy
Hepatology Unit "san Camillo"
Roma, Italy
Ospedale "Villa Betania"
Roma, Italy
IRCCS "L. Spallanzani"
Rome, Italy
IRCCS "Casa Sollievo della Sofferenza"
San Giovanni Rotondo, Italy
Infectious Diseases Unit Ospedale Civile
Sassari, Italy
Medicine Unit
Sassari, Italy
Infectious Diseases
Syracuse, Italy
SS. Annunziata
Taranto, Italy
Medicine Unit
Venosa, Italy
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.